Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Non-Current Assets (2016 - 2025)

Gyre Therapeutics (GYRE) has disclosed Non-Current Assets for 16 consecutive years, with $60.8 million as the latest value for Q3 2025.

  • On a quarterly basis, Non-Current Assets fell 13.66% to $60.8 million in Q3 2025 year-over-year; TTM through Sep 2025 was $244.1 million, a 4.8% decrease, with the full-year FY2024 number at $60.6 million, up 2.19% from a year prior.
  • Non-Current Assets was $60.8 million for Q3 2025 at Gyre Therapeutics, down from $61.4 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $70.4 million in Q3 2024 to a low of $773000.0 in Q3 2022.
  • A 5-year average of $30.1 million and a median of $5.0 million in 2021 define the central range for Non-Current Assets.
  • Peak YoY movement for Non-Current Assets: tumbled 83.1% in 2022, then skyrocketed 1357.6% in 2024.
  • Gyre Therapeutics' Non-Current Assets stood at $4.2 million in 2021, then soared by 738.51% to $35.1 million in 2022, then surged by 69.0% to $59.3 million in 2023, then rose by 2.19% to $60.6 million in 2024, then rose by 0.31% to $60.8 million in 2025.
  • Per Business Quant, the three most recent readings for GYRE's Non-Current Assets are $60.8 million (Q3 2025), $61.4 million (Q2 2025), and $61.3 million (Q1 2025).